FDA Will Soon Finalize Obesity Guidance, May Tackle CV Safety Separately
Executive Summary
The fuzzy regulatory picture for the challenging obesity space is about to come into focus with two actions from FDA: the agency is expected to issue final guidance on weight management drug development soon and, later, may consider requirements for proof of cardiovascular safety, in the vein of the recent guidance on diabetes drugs